Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease
Authors:
Open Access
- 9 May 2022
- journal article
- research article
- Published by Springer Nature in Translational Neurodegeneration
- Vol. 11 (1) , 1-19
Abstract
Background: Intracellular accumulation of the microtubule-associated protein tau and its hyperphosphorylated forms is a key neuropathological feature of Alzheimer’s disease (AD). Melatonin has been shown to prevent tau hyperphosphorylation in cellular and animal models. However, the molecular mechanisms by which melatonin attenuates tau hyperphosphorylation and tau-related pathologies are not fully understood.Methods: Immunofluorescence, immunoblotting analysis and thioflavin-S staining were employed to examine the effects of early and late treatment of melatonin on tau-related pathology in hTau mice, in which nonmutated human tau is overexpressed on a mouse tau knockout background. High-throughput microRNA (miRNA) sequencing, quantitative RT-PCR, luciferase reporter assay and immunoblotting analysis were performed to determine the molecular mechanism.Results: We found that both early and late treatment of melatonin efficiently decreased the phosphorylation of soluble and insoluble tau at sites related to AD. Moreover, melatonin significantly reduced the number of neurofibrillary tangles (NFTs) and attenuated neuronal loss in the cortex and hippocampus. Furthermore, using miRNA microarray analysis, we found that miR-504-3p expression was upregulated by melatonin in the hTau mice. The administration of miR-504-3p mimics dramatically decreased tau phosphorylation by targeting p39, an activator of the well-known tau kinase cyclin-dependent kinase 5 (CDK5). Compared with miR-504-3p mimics alone, co-treatment with miR-504-3p mimics and p39 failed to reduce tau hyperphosphorylation.Conclusions: Our results suggest for the first time that melatonin alleviates tau-related pathologies through upregulation of miR-504-3p expression by targeting the p39/CDK5 axis and provide novel insights into AD treatment strategies.Keywords
Funding Information
- National Natural Science Foundation of China (81901071, 81970993)
- Natural Science Foundation of Fujian Province (2019J01297, 2019J05072)
This publication has 77 references indexed in Scilit:
- Melatonin in Alzheimer’s DiseaseInternational Journal of Molecular Sciences, 2013
- Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the LiteratureJournal of Neuropathology & Experimental Neurology, 2012
- The Many Faces of TauNeuron, 2011
- Silencing of CDK5 Reduces Neurofibrillary Tangles in Transgenic Alzheimer's MiceThe Journal of Neuroscience, 2010
- Neuronal MicroRNA Deregulation in Response to Alzheimer's Disease Amyloid-βPLOS ONE, 2010
- Age-Dependent Impairment of Cognitive and Synaptic Function in the htau Mouse Model of Tau PathologyThe Journal of Neuroscience, 2009
- Alterations of the microRNA network cause neurodegenerative diseaseTrends in Neurosciences, 2009
- Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's diseaseJournal of Pineal Research, 2006
- Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levelsJournal of Pineal Research, 2003
- Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoformsJournal of Neurochemistry, 2003